SUMMARY
Steve R. Ommen, M.D., researches hypertrophic cardiomyopathy. The Mayo Clinic hypertrophic cardiomyopathy team assesses and improves treatment strategies for people with symptoms related to this condition. Sudden cardiac death is an important and devastating complication of hypertrophic cardiomyopathy. This complication requires a better understanding of risk markers and appropriate use of implantable defibrillators.
Dr. Ommen developed the world's largest, single-center clinical database of patients with hypertrophic cardiomyopathy and is systematically studying the genetic underpinnings and new therapies for this condition.
Focus areas
- New therapies for individuals with symptomatic, obstructive and nonobstructive hypertrophic cardiomyopathy.
- Identification of people with hypertrophic cardiomyopathy most likely needing surgery or invasive treatments.
- Sudden cardiac death risk assessment for people with hypertrophic cardiomyopathy.
Significance to patient care
Using Mayo Clinic's hypertrophic cardiomyopathy database, Dr. Ommen and his colleagues help individuals with hypertrophic cardiomyopathy be active and healthy and have typical life spans. He evaluates people with hypertrophic cardiomyopathy at Mayo Clinic and identifies which therapies are appropriate for each patient based on anatomy, severity of symptoms and health goals.